Protocol Ledger

NCT06648772 · Phase III · COMPLETED

Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

Interventional Phase III clinical trial protocol NCT06648772 sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-14 Enrollment: 190 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06648772
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)190 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06648772
Protocol FieldVerified Registry Value
NCT IdentifierNCT06648772
Consolidated Lead SponsorHangzhou Zhongmei Huadong Pharmaceutical Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment190 participants (ACTUAL)
Registered Start Date2024-11-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI